Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.

Fleischmann, Achim; Saramäki, Outi R; Zlobec, Inti; Rotzer, Diana; Genitsch Gratwohl, Vera; Seiler, Roland; Visakorpi, Tapio; Thalmann, George (2014). Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. Prostate, 74(16), pp. 1647-1654. Wiley-Blackwell 10.1002/pros.22882

[img] Text
pros22882.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (471kB) | Request a copy

BACKGROUND TMPRSS2-ERG gene fusion is the most frequent genetic alteration in prostate cancer. However, information about its distribution in lymph node positive prostate cancers and the prognostic significance in these advanced tumors is unknown. METHODS Gene fusion status was determined by fluorescence in situ hybridization on a tissue-microarray constructed from 119 hormone-naïve nodal positive, surgically treated prostate cancers containing samples from the primary tumors and corresponding lymph node metastases. Data were correlated with various tumor features (Gleason score, stage, cancer volume, nodal tumor burden) and biochemical recurrence-free, disease-specific, and overall survival. RESULTS TMPRSS2-ERG fusion was detected in 43.5% of the primary tumors. Conversely, only 29.9% of the metastasizing components showed the fusion. Concordance in TMPRSS2-ERG status between primary tumors and metastases was 70.9% (Kappa 0.39); 20.9% and 8.1% of the patients showed the mutation solely in their primary tumors and metastases, respectively. TMPRSS2-ERG fusion was not correlated with specific histopathological tumor features but predicted favorable biochemical recurrence-free, disease-specific and overall survival independently when present in the primary tumor (P < 0.05 each). CONCLUSION TMPRSS2-ERG fusion is more frequent in primary prostate cancer than in corresponding metastases suggesting no selection of fusion-positive cells in the metastatic process. The gene fusion in primary tumors independently predicts favorable outcome.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

04 Faculty of Medicine > Service Sector > Institute of Pathology > Autopsy
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology

UniBE Contributor:

Fleischmann, Achim; Zlobec, Inti; Rotzer, Diana; Genitsch Gratwohl, Vera; Seiler, Roland and Thalmann, George

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0270-4137

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

13 Feb 2015 08:05

Last Modified:

05 Nov 2015 13:51

Publisher DOI:

10.1002/pros.22882

PubMed ID:

25252136

Uncontrolled Keywords:

TMPRSS2-ERG, metastases, prostate cancer, survival

BORIS DOI:

10.7892/boris.63159

URI:

https://boris.unibe.ch/id/eprint/63159

Actions (login required)

Edit item Edit item
Provide Feedback